Triple combination antimicrobial regimen in the treatment of infections of neutropenic cancer patients.
Twenty-six cancer patients (pts) with chemotherapy-related neutropenic fever were treated with vancomycin 30 mg/m2/day i.v. every 12 hrs, imipenem 1500 mg/day i.v. every 8 hrs, and pefloxacin 800 mg/day i.v. every 12 hrs. Twelve fevers of unknown origin (FUO), 10 gram-positive, 3 gram-negative and 1 mycoplasma were also treated. Globally, cure was observed in 22 pts (84%) and failure in 4 pts (16%); in gram-positive infections alone, cure was observed in 10 pts (80%) and failure in 4 pts (20%). Defervescence was obtained within 3 days in 77% pts. No relevant side effects were observed.
Casali
A
A
Regina Elena Institute for Cancer Research, Rome, Italy.
Santini
S
S
Della Giulia
M
M
Di Lauro
L
L
Vici
P
P
Gionfra
T
T
Sega
F M
FM
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D005334:Fever / Q000188:drug therapy / Q000209:etiology; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy* / Q000209:etiology; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D015378:Imipenem / Q000627:therapeutic use*; D009175:Mycoplasma Infections / Q000188:drug therapy* / Q000209:etiology; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000382:microbiology*; D009503:Neutropenia / Q000139:chemically induced* / Q000188:drug therapy / Q000382:microbiology*; D015366:Pefloxacin / Q000627:therapeutic use*; D013845:Thienamycins / Q000627:therapeutic use*; D014640:Vancomycin / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D000970:Antineoplastic Agents; D013845:Thienamycins; D015366:Pefloxacin; D014640:Vancomycin; D015378:Imipenem